Banque Pictet & Cie SA Has $19.21 Million Stake in AstraZeneca (AZN)

Banque Pictet & Cie SA lifted its position in AstraZeneca (NYSE:AZN) by 5.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 279,684 shares of the company’s stock after purchasing an additional 13,705 shares during the period. Banque Pictet & Cie SA’s holdings in AstraZeneca were worth $19,207,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. US Bancorp DE boosted its position in shares of AstraZeneca by 8.8% during the first quarter. US Bancorp DE now owns 70,212 shares of the company’s stock worth $2,455,000 after acquiring an additional 5,651 shares during the last quarter. Signaturefd LLC boosted its position in shares of AstraZeneca by 21.4% during the first quarter. Signaturefd LLC now owns 11,657 shares of the company’s stock worth $408,000 after acquiring an additional 2,054 shares during the last quarter. Neuberger Berman Group LLC boosted its position in shares of AstraZeneca by 6.7% during the first quarter. Neuberger Berman Group LLC now owns 196,890 shares of the company’s stock worth $6,885,000 after acquiring an additional 12,339 shares during the last quarter. Pictet North America Advisors SA boosted its position in shares of AstraZeneca by 5.2% during the first quarter. Pictet North America Advisors SA now owns 278,434 shares of the company’s stock worth $19,121,000 after acquiring an additional 13,705 shares during the last quarter. Finally, Aperio Group LLC boosted its position in shares of AstraZeneca by 10.8% during the first quarter. Aperio Group LLC now owns 904,584 shares of the company’s stock worth $31,633,000 after acquiring an additional 87,994 shares during the last quarter. 15.18% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca opened at $36.50 on Thursday, MarketBeat Ratings reports. AstraZeneca has a 52 week low of $36.35 and a 52 week high of $36.55. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. The firm has a market cap of $92.25 billion, a price-to-earnings ratio of 8.53, a price-to-earnings-growth ratio of 1.93 and a beta of 0.61.

A number of equities analysts recently weighed in on AZN shares. Leerink Swann restated a “market perform” rating and set a $36.00 target price (up previously from $33.00) on shares of AstraZeneca in a research report on Thursday, January 18th. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. BMO Capital Markets restated a “buy” rating and set a $38.00 target price on shares of AstraZeneca in a research report on Friday, January 26th. ValuEngine upgraded shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 3rd. Finally, Sanford C. Bernstein upped their target price on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $38.12.

AstraZeneca Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply